A detailed history of Los Angeles Capital Management LLC transactions in Novo Cure LTD stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 15,267 shares of NVCR stock, worth $457,857. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,267
Holding current value
$457,857
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$15.61 - $23.34 $238,317 - $356,331
15,267 New
15,267 $238,000
Q2 2021

Aug 05, 2021

SELL
$130.4 - $225.58 $760,101 - $1.31 Million
-5,829 Reduced 79.22%
1,529 $339,000
Q1 2021

May 05, 2021

SELL
$124.11 - $190.17 $2.49 Million - $3.82 Million
-20,095 Reduced 73.2%
7,358 $972,000
Q4 2020

Feb 04, 2021

SELL
$112.16 - $174.14 $2.41 Million - $3.75 Million
-21,515 Reduced 43.94%
27,453 $4.75 Million
Q3 2020

Nov 02, 2020

SELL
$58.05 - $111.31 $8.47 Million - $16.2 Million
-145,955 Reduced 74.88%
48,968 $5.45 Million
Q2 2020

Aug 05, 2020

BUY
$57.2 - $74.41 $7.93 Million - $10.3 Million
138,595 Added 246.05%
194,923 $11.6 Million
Q1 2020

May 04, 2020

BUY
$57.05 - $95.75 $2.03 Million - $3.4 Million
35,545 Added 171.03%
56,328 $3.79 Million
Q4 2019

Feb 07, 2020

BUY
$68.3 - $93.8 $786,679 - $1.08 Million
11,518 Added 124.32%
20,783 $1.75 Million
Q3 2019

Nov 07, 2019

SELL
$61.86 - $97.8 $775,353 - $1.23 Million
-12,534 Reduced 57.5%
9,265 $693,000
Q2 2019

Jul 29, 2019

BUY
$42.22 - $63.23 $21,110 - $31,615
500 Added 2.35%
21,799 $1.38 Million
Q1 2019

Apr 25, 2019

BUY
$31.96 - $56.12 $680,716 - $1.2 Million
21,299 New
21,299 $1.03 Million
Q4 2018

Feb 11, 2019

SELL
$28.72 - $52.63 $1.04 Million - $1.91 Million
-36,244 Closed
0 $0
Q2 2018

Jul 31, 2018

BUY
$19.85 - $32.0 $719,443 - $1.16 Million
36,244 New
36,244 $1.13 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.15B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.